Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Intarcia Raises $215m As NDA For ITCA 650 Slips To Fourth Quarter

Executive Summary

Intarcia announced $215m in new equity financing and revised its NDA submission timeline for the second time since it reported positive Phase III results for ITCA 650 versus Januvia in mid-2015.

Advertisement

Related Content

VC Roundup: Infectious Disease Startup Snags $150m And Former Biogen CEO Scangos
Keeping Track: Approvals For Xultophy, Soliqua And Darzalex; NDAs From Intarcia And GSK; Complete Response For Green Cross
Biopharma Quarterly Dealmaking Statistics, Q3 2016
VC Roundup: Caribou Completes $30m Non-IPO CRISPR Financing; $205m In Cash For Five Others
Intarcia's Once-Yearly Diabetes Drug Bests Januvia
Intarcia boosts private cash with $1bn-plus Servier deal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register